Two doses of Covid-19 vaccine give 98% protection, says PGI study

The study, which didn't spe­cify the name of the vacc­ine, was conducted on Pun­jab police personnel

Vials, Vaccine
Of 35,856 individuals who re­c­eived the first dose, nine died of Covid | Photo: Shutterstock
BS Reporter New Delhi
1 min read Last Updated : Jul 02 2021 | 11:42 PM IST
A study on vaccine efficacy conducted by PGI Chand­igarh shows that two doses of the Covid vaccine gave 98 per cent protection against the disease, while one dose gave 92 per cent protection.

The study, which didn’t spe­cify the name of the vacc­ine, was conducted on Pun­jab police personnel. Of 35,856 individuals who re­c­eived the first dose, nine died of Covid. Among 42,720 who received both doses, there were two deat­hs.


“Deaths per thousand with a single dose was 0.25 and with both doses, it was 0.05,” V K Paul, member-health, Niti Aayog, said. Among 4,868 police personnel who did not receive any dose, there were 15 deaths due to Covid-19.


One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Coronavirus VaccineVaccinationVaccine

Next Story